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Abstract 
Purpose 
Amino acids are involved in many physiological processes in the body and serve as 
building blocks of proteins which are the main component of muscle mass. Often patients with 
cancer experience muscle wasting, which is associated with poor outcomes. The purpose of this 
paper is to discuss amino acid kinetics in cancer, review the evidence on the response to 
nutrition in patients with cancer, and to give recommendations on the appropriate level of 
amino acid or protein intake in cancer.  
Current evidence shows that amino acid kinetics in patients with cancer are disturbed, 
as reflected by increased and decreased levels of plasma amino acids, an increased whole body 
turnover of protein and muscle protein breakdown. A few studies show beneficial effects of 
acute and short-term supplementation of high protein meals or essential amino acid mixtures 
on muscle protein synthesis.  
Conclusion 
Cancer is associated with disturbances in amino acid kinetics. A high protein intake or 
supplementation of amino acids may improve muscle protein synthesis. Future research needs 
to identify the optimal level and amino acid mixtures for patients with cancer, in particular for 
those who are malnourished.  
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Introduction 
Amino acids are the building blocks of proteins and polypeptides and regulate key 
metabolic pathways that are necessary for maintenance, growth, reproduction, and immunity. 
They are key precursors for hormone synthesis and other nitrogenous substances involved in 
body functions. As such, maintaining physiological concentrations of amino acids and their 
metabolites (e.g. nitric oxide or serotonin) are essential and in contrast cases elevated levels of 
amino acids and related products (e.g. ammonia or homocysteine) can be harmful and cause 
neurological disorders, oxidative stress and cardiovascular disease (Deutz et al. 2017). For 
homeostasis, the body requires an optimal balance of amino acids in the diet and the 
circulation (Wu 2009).  
The growth of cancer leads to alterations in the host’s metabolism. For example, 
proinflammatory cytokines produced by or in response to the tumor stimulate the synthesis of 
acute phase protein reactants and can interact the neuroendocrine axis resulting in anorexia 
and increased energy expenditure, increasing the requirements for protein and energy. Under 
these circumstances, there is an ongoing, progressive, breakdown of muscle mass and fat tissue 
(Khalid et al. 2007; Engelen M.P. et al. 2016; Argilés 2017). However, there is a variability in 
energy demands in cancer with some patients showing to be hypometabolic (REF Lelbach 
2007). In these instances, there is evidence to suggest that patients compensate with reduced 
physical activity levels (REF Moses 2004). Despite metabolic alterations, a few studies have 
demonstrated that patients with cancer can reach muscle protein anabolism with oral or 
parenteral amino acid nutrition supplements or protein-rich meals (Deutz et al. 2011; Peters et 
al. 2011; van Dijk et al. 2015; Engelen M. P. et al. 2016). However, tumor-induced anorexia and 
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physiological changes associated with the tumor, such as obstruction and dysphagia and 
potential malabsorption and maldigestion often diminish food intake (Argilés 2017). This can be 
exacerbated by anti-cancer treatment-related side effects such as nausea, vomiting and 
dysgeusia (Sánchez-Lara et al. 2010; Hébuterne et al. 2014; Arends et al. 2017). 
Weight loss (DeWys et al. 1981; Prado et al. 2013; Hébuterne et al. 2014; Martin et al. 
2014) and malnutrition are prevalent in patients with cancer. Recent studies have shown that 
up to 50% of patients with cancer are malnourished or at risk of malnutrition based on their 
degree of involuntary weight loss (usually more than 5% in 1 month, or more than 10% in 6 
months) (Hébuterne et al. 2014; Gioulbasanis et al. 2015).  
The progressive loss of skeletal muscle mass and strength or physical function is known 
as sarcopenia (REF Cruz-Jentof, 2010). When seen in patients with a high percentage of body 
fat, it is called ‘sarcopenic obesity’ (Carneiro et al. 2016).On average, 39% (11-74%) of patients 
with cancer experience muscle wasting or sarcopenia (Pamoukdjian et al. 2017) depending on 
the stage and type of cancer (Shachar et al. 2016).  
Cancer cachexia  is also a syndrome of progressive weight loss and muscle wasting that 
is also characterized by anorexia, inflammation, insulin resistance and muscle protein 
breakdown (Fearon K et al. 2011; Cederholm et al. 2017). By definition, the muscle loss in 
cancer cachexia cannot be fully reversed by conventional nutrition support (i.e. provision of 
oral, enteral or parenteral nutrition to maintain or restore optimal nutrition status and health 
(REF ASPEN: 
http://www.nutritioncare.org/About_Clinical_Nutrition/What_is_Nutrition_Support_Therapy/) 
(Fearon K et al. 2011). This is due to the complexity of the cancer cachexia syndrome and the 
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suspected anabolic resistance, in particular in advanced disease (‘refractory cachexia’) (REF 
Fearon 2011).   
Both the amount and the quality of muscle in the body are relevant to patients with 
cancer. A low muscle mass is associated with a poorer quality of life (Hung et al. 2013), 
postoperative complications (Härter et al. 2017; Rutten et al. 2017), higher treatment toxicity 
and shorter survival (Deans et al. 2009; Prado et al. 2013; Martin et al. 2014; Tanaka et al. 
2017). Sarcopenia is associated with muscle weakness (Cruz-Jentoft et al. 2010; Biolo Gianni et 
al. 2014; Naito et al. 2017). Several studies show that patients with cancer experience muscle 
weakness in those undergoing chemotherapy (Gilliam and St Clair 2011; Vermaete et al. 2014; 
Midgley et al. 2017; Teodozio et al. 2017), stem cell transplant (Tanaka et al. 2017) and even 
those without active treatment (Norman Kristina et al. 2010; Vermaete et al. 2014; Owusu et al. 
2017). Muscle quality refers to the amount of contractile vs. non-contractile muscle and muscle 
composition, including the amount of intramuscular fat droplets (reflected by muscle 
attenuation on CT scans). Skeletal muscle attenuation is associated with increased 
postoperative complications and shorter survival (Sjøblom et al. 2016; Silva de Paula et al. 
2018). 
 Certain chemotherapy regimens and hormonal alterations affect protein and fat 
metabolism and food intake (Argilés et al. 2015). This often results in weight gain and fat 
deposition in so-called ‘adiposity-related cancers’, such as breast, endometrial and prostate 
cancer (Allott and Hursting 2015; Keum et al. 2015; van den Berg et al. 2017). This side effect of 
cancer treatment is also problematic, as obesity or a high percentage of body fat are associated 
with shorter survival (Martin et al. 2013). 
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To develop and test interventions targeting muscle wasting in cancer, we need to 
understand the metabolic processes behind muscle wasting. The aim of this review is to discuss 
amino acid kinetics in cancer and the response to nutrition in patients with cancer. We will 
provide recommendations about the optimal intake of amino acids for patients with cancer and 
discuss areas for future research.  
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Changes in plasma and muscle amino acids in cancer 
Disturbances in amino acid metabolism 
Amino acids are basic metabolites and metabolic regulators that circulate in the plasma 
for transport to peripheral tissues (Lai et al. 2005). In the presence of a tumor the demand for 
amino acids increases and there is a corresponding increase in protein turnover (i.e., the 
balance between muscle protein synthesis and breakdown) (Jeevanandam et al. 1984). This is 
exacerbated by inflammation as there is an increased proportion of splanchnic amino acids that 
are extracted to support the hepatic synthesis of acute phase protein response reactants 
(Jonker et al. 2012). There is preferential consumption of certain amino acids, in particular 
essential amino acids (EAAs) (Proenza et al. 2003; Jonker et al. 2012). In terms of non-essential 
amino acids (NEAAs) there is a demand for glutamine, glycine and aspartate to support tumor 
growth and serine for membrane lipid component synthesis.  
Skeletal muscle is a reservoir of amino acids, glucose and intramuscular lipids that can 
support protein synthesis or energy production elsewhere in the body, for instance for the 
formation of glucose or glycogen (Perriello et al. 1997; Brook et al. 2017). In cancer, the 
homeostatic regulation of protein turnover is disturbed. The increased demands for energy can 
upregulate muscle protein breakdown to provide amino acid substrates for glucose and 
glycogen formation, causing protein depletion and loss of skeletal muscle mass (Brook et al. 
2017). Further, muscle protein synthesis is diminished (as discussed later) and increased muscle 
apoptosis contributes to a negative muscle protein balance (Argilés 2017). 
Energy balance can be altered by decreased food intake and hypermetabolism. One of the 
factors of hypermetabolism is mitochondrial dysfunction, which causes decreased ATP 
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synthesis and oxidative phosphorylation uncoupling and reduces energy efficiency (Argilés 
2017). Triggered by inflammatory mediators, white adipose cells are converted into brown 
adipose cells, which promote heat production and energetic inefficiency (Argilés 2017). The 
severity of metabolic disorders in cancer depends on the extent of the host response, which is 
dependent on the stage and type of the cancer (Fearon K et al. 2011). The following paragraphs 
give an overview of studies investigating alterations in plasma and muscle amino acids in 
patients with cancer.  
Plasma amino acid concentrations 
Profiles of plasma free amino acids in cancer can be influenced by several factors, one of 
them being dietary intake. When protein from the diet is digested and absorbed by the gut, 
amino acids are extracted by the splanchnic area or released into the systemic circulation. In 
this way, dietary protein intake and starvation impact on plasma amino acid concentrations 
(Jonker B J Nutr2012, S139-S148). Further, disease, inflammation and anti-cancer treatments 
may alter the absorption, digestion or utilization of amino acids resulting in enhanced 
endogenous protein breakdown consequently altering plasma amino acid profiles.  In cancer 
this could be more profound because of the metabolic demands of the tumour, requiring amino 
acids for protein synthesis and tumour growth (Jonker B J Nutr2012, S139-S148, then Have 
2007 S23-S36). 
Several studies investigated plasma amino acid profiles (Table 1) and documented 
significant differences between patients with cancer and healthy subjects. Few studies have 
investigated differences between early and late stage cancers, and some explored these 
profiles in patients with anorexia and weight loss. This section discusses studies investigating 
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plasma amino acid concentrations in cancer that have been published in the last 15 years 
(Vissers et al. 2005; Miyagi et al. 2011; Shen et al. 2013; Ihata et al. 2014; Ma et al. 2014; 
Fukutake et al. 2015). .  
Lai et al. (2005) reviewed 13 clinical studies in patients with heterogeneous cancer 
types. Lai proposed that patients with cancer exhibited a specific ‘cancer-related’ amino acid 
profile, of reduced levels of plasma alanine, arginine, aspartate, citrulline, cysteine, glutamine, 
glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, taurine, 
threonine, tryptophan, tyrosine and valine, and elevated levels of plasma ornithine. More 
specifically, Lai et al. (2005) found that plasma amino acids were frequently elevated in breast 
cancer (specifically alanine, arginine, proline and tryptophan). Similarly, Miyagi et al. (2011) 
found increased levels of amino acids in patients with breast cancer. In contrast to Lai et al. 
(2005) and Miyagi et al. (2011), our investigation of the metabolism of arginine and the 
interrelated amino acids glutamine and citrulline in cancer (see Figure 1)  revealed lower 
plasma arginine, citrulline and glutamine concentrations in pre-surgical patients with early 
stage breast cancer compared with healthy controls (Engelen M.P. et al. 2016). Further we 
found that weight-stable patients with T1 to T3 breast cancer had decreased plasma arginine 
(not glutamine or citrulline) and other amino acids such as tryptophan and arginine (Vissers et 
al. 2005). This was especially visible in those with ripple-negative breast cancer. Thus, findings 
in patients with breast cancer are inconclusive, which could be explained by differences 
between individual studies in the type and stage of breast cancer and the type of treatment 
(e.g. surgery vs. palliative care). 
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Further to the findings in breast cancer, Lai et al. (2005) found that plasma amino acids 
were frequently depressed in digestive organ cancers, but there were no discernable trends in 
other cancers. Miyagi et al. (2011) also found decreased levels in patients with gastric and 
colorectal cancers.  Our group  showed similar results where plasma levels of arginine were 
decreased in patients with colonic (Vissers et al. 2005), pancreatic (Vissers et al. 2005) as well as 
lung (Engelen M.P. et al. 2016) cancer. In gynecological cancers, plasma amino acids have been 
investigated as potential biomarkers for diagnosis and monitoring of disease. Turkoglu et al. 
(2016) systematically reviewed metabolomics studies in human ovarian cancer and concluded 
that plasma concentrations of glutamine, glutamate, cysteine, glycine and threonine were 
increased and L-tryptophan and phenylalanine were decreased in ovarian cancer. Plasma valine 
and alanine could be either increased or decreased (Turkoglu et al. 2016). In endometrial 
cancer, plasma valine, tryptophan and phenylalanine were decreased in patients with cancer 
compared to age- and BMI-matched control subjects (Ihata et al. 2014).  
Importantly, advanced disease and malnutrition were associated with more profound 
changes in plasma amino acids in some studies, as indicated by Lai et al. (2005). It has been 
suggested that increased muscle protein breakdown provides substrates for enhanced 
gluconeogenesis in the liver and enhanced branched chain amino acid (BCAA) oxidation in 
muscle. This would result in normal or higher BCAA levels in early-stage cancer. In late-stage 
cancer, muscle protein breakdown can cease as the tumor progresses, as reflected by lower 
levels of BCAA and EAA (Lai et al. 2005; Turkoglu et al. 2016). This hypothesis is in contrast with 
Miyagi et al. (2011) findings that changes in plasma amino acids are independent of 
malnutrition or tumor progression. Miyagi reported decreased concentrations in plasma amino 
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acids profiles in patients with both early and late stage disease, where patients with early stage 
disease did not have significant weight loss, anorexia or serum albumin depletion. 
In order to assess cancer cachexia risk by examining amino acid concentration and 
analyzing amino acid balance, Kitagawa et al. (2017) conducted a retrospective chart review of 
consecutive patients with unresectable advanced gastrointestinal cancer (stage IV) receiving 
chemotherapy treatment. Results showed that an increase in psoas (hip flexor) muscle index 
over time was related to a lower EAA/total amino acid (TAA) ratio. Serum C-reactive protein 
(CRP), leucine, and isoleucine were negatively correlated with increases in muscle index and 
there was a strong negative correlation between serum CRP and change in muscle index. This 
suggests that when EAAs are used for muscle build up plasma EAA/TAA ratios decline, whereas 
skeletal muscle protein breakdown was associated with higher plasma EAA/TAA ratios. 
In conclusion, many studies have shown that patients with cancer have altered levels of 
plasma amino acids. Alterations in plasma amino acids can be present in early-stage patients 
who are in a good nutritional status. There is conflicting evidence whether plasma amino acid 
variations are more profound in patients with metabolic alterations, metastatic cancer, 
anorexia, weight loss and/or malnutrition. Although most studies investigated fasted plasma 
samples, this was unclear for a few studies, complicating the interpretation and collation of 
results. Also, more controlled research is needed to clarify the value of using plasma amino acid 
profiles to be used as a marker for cancer screening and diagnosis.  
Cancer, muscle wasting, sarcopenia and cachexia can alter the plasma profile of amino 
acids, but whether there is a resultant change in the amino acid profile of muscle tissue is less 
clear. Muscle serves as a major reservoir of amino acids, containing approximately half of the 
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body’s free amino acid pool (de Blaauw et al. 1997). Evaluating muscle amino acids requires 
invasive techniques such as muscle biopsy. Therefore, in patients with cancer, whole body 
protein turnover is often evaluated using radioactive or, more commonly, stable isotope 
techniques. 
In a recent review by Engelen MPKJ et al. (2016), it was noted that the rate of whole 
body protein turnover was highly variable across patients with cancer and likely influenced by 
the presence and magnitude of inflammation associated with cancer. For example, in a study 
of11 mostly  malnourished patients with colorectal cancer, Carmichael et al. (1980) showed 
whole body protein turnover was significantly higher in patients with cancer than in non-cancer 
controls. In these patients, the rate of protein synthesis and breakdown increased  with the 
advancement of cancer, but was significantly lower in patients with anorexia.  When compared 
with weight-stable controls, van Dijk et al. (2015) found that patients with pancreatic cancer 
had higher whole body protein turnover where protein breakdown was associated with CRP. 
Both the rate of protein breakdown and synthesis were significantly higher in weight-losing 
patients  versus weight-stable non-cancer controls. The rate of protein synthesis in the cancer 
group did not respond to sip feeds, but the rate of protein breakdown decreased enabling 
patients to reach a positive protein balance. Similarly, Williams et al. (2012) showed that pre-
operative fasted muscle protein synthesis rates of colon cancer patients were comparable to 
those of healthy controls. However, unlike healthy controls, there was no muscle synthetic 
response to feeding. There was a trend for increases under fed and fasted conditions in pre-
operative muscle protein breakdown compared with healthy controls, but this was not 
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statistically significant. However, after the surgical removal of the cancer, both synthesis and 
breakdown normalized to the rates demonstrated by healthy controls. 
Fearon KC et al. (1988) showed that patients with lung and colon cancer had 
significantly higher rates of whole body protein turnoverand breakdown but comparable rates 
of synthesis compared with non-cancer controls. When analyzed by weight status, there were 
no differences between weight-losing (>5% weight loss) and weight-stable patients with 
cancer.In contrast, MacDonald et al. (2015) found that myofibrillar protein breakdown was 
comparable, but there were significantly higher protein synthetic rates in weight-losing versus 
weight stable patients with early stage gastric cancer, In 
 In Dworzak et al. (1998) found the rate of whole body protein turnover was comparable 
between patients with advanced gastric cancer and healthy controls.When evaluated across the 
forearm muscle, the rate of muscle protein synthesis was significantly lower in the cancer 
group. These studies suggest that differences in whole body protein turnover are likely 
associated with inflammation, nutritional status, tumor presence and cancer stage.  
Anabolic stimuli in cancer 
Dietary protein 
Many factors contribute to the activation of protein breakdown in cancer. The 
expression of proteolysis-inducing factor (PIF) by tumors induces enhanced protein 
breakdown(Argilés 2017). The ubiquitin-proteasome and autophagic-lysosomal pathways are 
upregulated exacerbating skeletal muscle protein breakdown. There are changes in the rate of 
myogenesis and apoptosis, decreasing the regenerative capacity of skeletal muscle and 
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increasing the rate of cell death. Other factors include inflammatory cytokines, the activation of 
NF-kappa B and the suppression of mTOR activity.  
As a result of the enhanced inflammatory response and protein breakdown , there is an 
increased need for dietary protein in cancer (Guadagni and Biolo 2009). However, often 
patients with cancer have a reduced nutritional intake as a consequence of anorexia and 
symptoms related to the tumor or caused by cancer treatments (Sánchez-Lara et al. 2010; Coa 
et al. 2015). A few studies investigated the relation between protein intake and clinical 
outcomes in patients with cancer. Stobaus et al. (2015) showed that in 285 patients with mixed 
types of cancer undergoing chemotherapy, 66% had a low protein intake (<1 g/kg body 
weight)(REF Arends 2017), and a low protein intake was associated with a more than twofold 
higher risk of cancer-related fatigue and 6-month mortality. In a smaller study in 41 patients 
with breast cancer undergoing chemotherapy, dietary intake was not correlated with health-
related quality of life (Lua et al. 2012). In a study in 50 patients with cancer admitted to the 
hospital, 33% of all patients did not reach daily energy requirements of 25 kcal/kg and 23% had 
a dietary protein intake of less than 1 g protein/kg/day. A protein intake of < 1 g/kg/day was 
associated to a poorer self-reported physical functioning and fatigue. No significant differences 
were found regarding caloric intake and QoL (Trabal et al. 2006). Bosaeus et al. (2002) 
investigated dietary intake, energy metabolism and weight loss in 297 patients with generalized 
malignant disease undergoing palliative care involving anti-inflammatory treatment and 
nutritional counselling during 4 months. At enrollment, dietary energy and protein intake were 
low. Energy intake slightly increased during the intervention period and a higher dietary energy 
intake predicted longer survival. There was no correlation between protein intake and survival.  
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A study in outpatients with mixed types of cancer who were at high risk of malnutrition 
or malnourished showed that individual nutritional therapy provided by a dietitian vs. standard 
care for 3 months improved daily energy and protein intake (+379kcal and +10.g protein, 
respectively, P<0.05), but this was not associated with improvements in nutritional status, 
physical functioning, or quality of life (Uster et al. 2013). In a RCT in head and neck cancer, 
patients who received dietary counseling had a higher energy and protein intake during 
radiotherapy compared to patients receiving only supplements or usual care (+521kcal vs. 
+322kcal and -400kcal, and +26g, +35g, -15gd protein, respectively, P<0.01). They also reported 
a better QoL and a reduced incidence or severity of RT toxicity symptoms after 3 months 
(Ravasco et al. 2005). Baldwin et al systematically reviewed effects of oral nutritional 
interventions for patients with cancer, and showed that these are effective at increasing energy 
intake with 432 kcal/d  and improving some aspects of quality of life (Baldwin et al. 2012). In 
conclusion, nutritional counseling and oral nutritional interventions in patients with cancer 
improve dietary intake and quality of life, however body composition and survival were not 
investigated in these studies.  
We only identified two studies on the relationship between dietary intake and muscle 
mass in patients with cancer. There are a few, small studies investigating the short-term effect 
of protein and amino acid-enriched nutrition supplements on muscle anabolism in patients with 
cancer. Although some amino acid-enriched nutrition supplements (e.g., BCAAs) appear to 
overcome the anabolic resistance of muscle in cancer, it is less clear whether the anabolic 
effects would be sustained with longer-term supplementation and what the overall effects on 
muscle quantity, quality and function would be. Studies on supplementation of glutamine in 
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catabolic conditions looking at effects on chemotherapy toxicity show inconsistent results. 
There are currently no guidelines with regards to the minimal threshold of protein per meal or 
mid-meal, and the optimal number and frequency of high-protein meals throughout the day.  
In conclusion, dietary protein intake is often suboptimal in patients with cancer. Some 
studies found an association between protein intake levels, either or not established by 
nutritional therapy or supplements, and quality of life and survival, but more research is 
needed to confirm this.  
What is the optimal amount of amino acids/protein in patients with cancer?  
 
The most recent evidence-based dietary guidelines for patients with cancer, published 
by the European Society for Clinical Nutrition and Metabolism(ESPEN), recommend a protein 
intake of at least 1 g per kg body weight per day, if possible up to 1.5 g/kg/day (Arends et al. 
2017). Expert opinions suggest the optimal range of dietary protein for patients with cancer to 
be 1.0-2.0 g/kg/day. This is based on existing acute studies focused on metabolic endpoints and 
benefits, not on long-term studies showing benefits on muscle maintenance. These studies 
showed that an elevated protein intake promoted muscle protein anabolism in patients with 
cancer (Winter et al. 2012; Baracos 2015; MacDonald et al. 2015). A critical literature appraisal 
by Bozzetti (2013) concluded that the dose of amino acids capable of supporting a positive 
protein balance in patients with cancer might be close to 2 g/kg/d. The ESPEN committee also 
stated that protein in doses up to and above 2 g/kg/d are safe; in patients with acute or chronic 
renal failure protein supply should not exceed 1.0 or 1.2 g/kg/d, respectively (Arends et al. 
2017). The clinical guidelines of the American Society of Parenteral and Enteral Nutrition 
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(ASPEN) for nutrition support during adult anticancer treatment do not provide specific 
guidelines for amino acids or protein (August and Huhmann 2009).  
There is concern that estimating equations based on body weight would fail to account 
for the variability in body composition (Geisler et al. 2016). This concern is particularly relevant 
in cancer where sarcopenia, especially sarcopenic obesity and cancer cachexia are prevalent. 
Current recommendations of 1g/kg body weight/day might under- or over- estimate protein 
requirements for lean mass. 
This concept was explored by Geisler et al. (2016) in a recent theoretical exercise where 
protein requirements were estimated based on lean mass instead of body weight. Geisler et al. 
(2016) calculated lean mass (CT at the L3 landmark), and assumed a dietary protein intake  of 
0.8g/kg BW/day for 547 patients with stage III/IV non-small cell lung cancer .  Under these 
assumptions, 97.4% of patients would present with low protein intake per kg of lean mass. 
Although this exercise was based on multiple assumptions (for example, assumed dietary 
protein intake based on data from healthy subjects), the variation in lean mass of patients with 
cancer indicates that further study is required. Protein quality is the extent to which the amino 
acids of a certain protein match the amino acid needs of the consumer, and the efficiency with 
which the amino acids are extracted from the diet and uses them for growth or maintenance 
purposes (Marinangeli and House 2017). In 2012, the FAO suggested to express protein quality 
as the ‘digestible indispensable amino acid score’ or DIAAS which takes into account the 
content, pattern and bioavailability (including digestibility) of EAAs (Marinangeli and House 
2017). Protein quality differs between dietary sources, and therefore the FAO recommends a 
consumption of a significant amount of high-quality proteins on a daily basis for all healthy 
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subjects. Table 2 displays the DIAAS for common protein-rich foods and shows that in general, 
animal-based foods have a higher DIAAS than plant-based foods. The ESPEN guidelines (Arends 
et al. 2017) also recommend good quality protein from animal, fish, dairy and plant sources for 
the majority of patients with cancer requiring nutrition support for a short period of time. 
Increasing dietary protein intake should satisfy any increase in protein demand thereby 
preventing muscle wasting. There has been little success of nutrition interventions in reversing 
or preventing muscle wasting suggesting muscle protein anabolic resistance.  
When excluding studies that investigate the effects of high-protein supplements or sip 
feeds, two studies have investigated the relation between dietary protein intake and muscle 
mass in patients with head and neck cancer. In 69 patients, BIA was used to assess body 
composition before, during and at the end of radiotherapy or chemoradiation. All patients 
received nutritional counselling, with the majority (95%) receiving ONS. A dietary intake of 
≥75% of the recommended energy and protein intake was considered as compliant (n=18). 
They found that compliant patients maintained weight and fat free mass over time, whereas in 
noncompliant patients these decreased significantly. A limitation of this study was that 
mucositis was less common in compliant patients than in noncompliant patients (11.1% versus 
88.9%, resp.) (Hopanci Bicakli et al. 2017). Pistoia et al. (2012) investigated food intake in 62 
patients with head and neck cancer undergoing radiotherapy. In three weeks, dietary energy 
intake reduced from 26.5 to 21.3 kcal/g/d and protein intake from 1.19 to 0.93 g/kg/d and 
there were significant reductions in arm muscle area and arm muscle circumference. 
In addition to the studies on dietary protein intake in relation to clinical outcomes which 
will be discussed in the next paragraph, studies investigating the anabolic potential of muscle 
20 
generally employ stable isotope techniques that enable the calculation of muscle protein 
synthesis and breakdown rate in response to feeding. For example, Emery et al. (1984) study of 
5 weight-losing men with cancer, anorexia and reduced dietary intake vs healthy controls 
showed that the rate of muscle protein synthesis in the fed state was significantly lower than in 
the healthy controls. Similarly, Williams et al. (2012) found that although muscle protein 
breakdown was comparable between preoperative patients with colon cancer and non-cancer 
controls, the increases in muscle protein synthesis in response to feeding were not evident in 
the patients with cancer. Conversely, there is some clinical evidence that patients with cancer 
do have a muscle protein anabolic potential. In a study of 3 month body composition analysis, 
Prado et al. (2013).showed that in 368 advanced patients with cancer, 45% maintained and 15% 
gained muscle mass. Medical chart review demonstrated that this was likely due to periods of 
stable disease, symptom control as well as a patient’s ability to eat and function. 
In summary, patients with cancer experience a disturbed amino acid metabolism, 
upregulated catabolic processes (enhanced ubiquitin mRNA levels and proteasome activity) in 
skeletal muscle and hepatic acute phase response. The current guidelines regarding the use of 
dietary amino acids and protein are unlikely to satisfy the aims of nutrition therapy,  mitigate 
metabolic derangements and maintain skeletal muscle mass.  
 
The effect of amino acids supplementation on metabolism and clinical outcomes 
It is possible that muscle protein synthesis cannot be stimulated with conventional 
nutrition support in patients with cancer who exhibit muscle wasting, sarcopenia and/or 
cachexia. For example, although van Dijk et al. (2015) found that a commercially available 
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supplement stimulated an anabolic response comparable to that of non-cancer controls, this 
was only achieved through the reduction of protein breakdown as there was no corresponding 
response in protein synthesis. 
There is still potential for specialized nutrition interventions that target anabolic 
pathways and provide the substrates for muscle protein synthesis. These may include EAA 
mixtures or high quality proteins, potentially combined with immune-modulating nutrients such 
as omega-3 polyunsaturated fatty acids. This idea was explored in Engelen MPKJ et al. (2016) 
review of whole body protein turnover studies who state it is possible to at least partly 
overcome anabolic resistance through the provision of high quality proteins. Amino acids are 
the principal nutrient responsible for stimulating muscle protein synthesis (Wolfe 2002). 
However, when supplementing with amino acids to simulate synthesis a number of factors 
should be considered. Firstly, only EAAs are required to stimulate muscle protein synthesis. 
Tipton et al. (1999) and Wolfe (2002) both showed that NEAAs confer no additional benefit 
over providing the same amount of EAAs alone. Secondly, it appears that the increasing plasma 
concentration of EAAs in response to supplementation trigger synthesis, irrespective of the 
absolute plasma concentration (Wolfe 2002). Thirdly it is possible that there is a limit to the 
extent to which synthesis can be stimulated during constant intake, with doses of amino acids 
exceeding 20g already exceeding the maximal effective dose in healthy volunteers (Wolfe 
2002). Conversely, Engelen MPKJ et al. (2016) showed a linear relationship between dietary 
EAA availability and net protein gain existed in weight-stable patients with non-small cell lung 
cancer and weight-losing patients with pancreatic cancer that was comparable to healthy 
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controls. This model suggests that higher amounts of EAAs might be useful to patients with 
cancer.  
Branched Chain Amino Acids (BCAA) 
Arguably the most important amino acids are the BCAAs; a subset of EAAs comprised of 
leucine, isoleucine and valine. Not only are they substrates for muscle protein synthesis and 
energy metabolism, but leucine is also a key regulator of protein synthesis and breakdown. 
Under normal conditions, the oxidation of BCAA provides up to 7% of energy, but in highly 
catabolic states this can be as high as 20% (Choudry et al. 2006). The ESPEN guidelines state 
that there is some evidence that parenteral nutrition containing BCAA result in an improved 
protein accretion and albumin synthesis when compared to a standard amino acid solution. A 
number of trials in patients with cancer comparing varying proportions (e.g., 25% vs 45% of 
protein) of BCAA-enriched parenteral nutrition in surgical patients with cancer have been 
reviewed (Choudry et al. 2006). Although early studies showed some potential benefits of BCAA 
provision, results from all clinical trials were generally inconsistent in terms of effect on 
indicators of muscle wasting, muscle amino acid uptake, morbidity and mortality (Choudry et al. 
2006).  
Dioguardi (2011) proposed an alternative nutrition formula of more than 80% EAAs 
(predominantly BCAAs). The NEAA tyrosine was included as it is only non-essential for the liver 
and the NEAA cysteine was included to prevent methionine from transforming into 
homocysteine (a toxic intermediate in the methionine to cysteine pathway (Figure 2). This 
BCAA-enriched formulation has been trialed in few small studies to date reporting 
improvements in lean muscle mass of sarcopenic elderly subjects (Solerte et al. 2008) and 
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weight, albumin and total protein in hemodialysis patients (Bolasco et al. 2011). The most 
relevant study to cancer was a single-arm, uncontrolled trial conducted in 25 cachectic patients 
with advanced cancer. After 8 weeks of supplementation, patients had no significant change in 
weight, BMI, lean body mass (via BIA) or fatigue. There were significant improvements in hand 
grip strength, albumin and significant reduction in reactive oxygen species (Madeddu et al. 
2010). The limitations of this study were its small sample size, lack of control group and 
heterogeneous mix of patients with cancer in relation to tumor type. Further research is 
needed to investigate long-term effects of supplementation with body composition analysis 
sensitive to small changes in muscle mass (e.g., CT). 
Leucine and β-hydroxy-β-methylbutyrate (HMB) 
One of the most potent activators of muscle protein synthesis is the BCAA leucine. The 
dose-response effect of leucine on muscle protein synthesis has been demonstrated in mouse 
cancer cachexia models where a leucine-enriched diet resulted in greater maintenance of lean 
muscle mass compared with those on a standard diet (Peters et al. 2011). Administration of 
amino acids as an oral nutrition supplement enriched in leucine and n-3 fatty acids in humans 
can increase muscle protein synthesis compared to a conventional supplement (Arends et al. 
2017). For example, Deutz et al. (2011) demonstrated in a study where a leucine-enriched high 
protein medical food (27% calories as protein including 4.16g free leucine) increased muscle 
protein synthesis rate by 40% after 5 hours. Consistent with previous studies, the conventional 
medical food did not elicit a change in the rate of muscle protein synthesis.  
About 0.1% of leucine is converted into Β-hydroxy-β-methylbutyrate (HMB) (Engelen 
and Deutz 2018). Although HMB has been shown to reduce skeletal muscle protein breakdown 
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and inflammation as well as stimulate muscle protein synthesis, studies in cancer are limited. In 
an RCT of 32 weight-losing patients with cancer, a daily dose of 3g HMB/14g arginine/14g 
glutamine supplement versus an isonitrogenous mix of NEAAs resulted in a 1kg gain in fat-free 
mass in the supplement group (May et al. 2002). One of the larger trials of 
HMB/Arginine/Glutamine was conducted in 472 weight-losing patients with advanced  cancer. 
Unfortunately, although there was a trend towards higher lean mass, statistical significance was 
not reached, possibly due to insufficient data with only 37% of participants completing the 
protocol (Berk et al. 2008). 
Glutamine 
BCAAs serve as precursors for alanine and glutamine synthesis (Figure 3) and much of 
their beneficial effects during catabolism are likely related to the subsequent synthesis of 
glutamine and blunted release of glutamine from skeletal muscle (Choudry et al. 2006). 
Glutamine is a key factor in maintaining cellular and vital organ function and modulating 
immune cell activity (Nicastro et al. 2012). In cachexia, the use of glutamine as a substrate by 
immune cells is greatly increased, dropping plasma levels. This is compounded by an increase in 
tumor and splanchnic tissue update and a decrease in skeletal muscle synthesis (Jonker et al. 
2012).  
Some studies have demonstrated that supplementation with glutamine may improve 
nutritional parameters and morbidity around surgery and chemotherapy.. For example, in a 2 
day crossover trial (Biolo G. et al. 2006) of 6 patients with colorectal and cervical cancer, 2 leg 
muscle metabolic studies were conducted within the first 48 hours of radical resection with 
intraoperative radiation therapy comparing an infusion of balanced amino acid with a BCAA-
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enriched solutions (leucine/TAA(g) of 0.09 and 0.22, respectively). Biolo G. et al. (2006) found 
that although the balanced amino acid solution did not affect outcomes, the BCAA-enriched 
solution accelerated muscle protein turnover by increasing protein and de novo glutamine 
synthesis. In a review of the effects of glutamine supplementation on chemotherapy toxicity, 
Kuhn et al. (2010) found that only ⅓ of the studies using oral and ½ of those using parenteral 
glutamine reported a clinical benefit. 
Arginine and citrulline 
Arginine is a semi-EAA with required for adequate nitric oxide synthesis (Figure 1) and 
necessary for immune function, cell regeneration, tissue perfusion and wound healing. It has a 
direct and possible indirect stimulation of muscle protein synthesis through its regulation of the 
mTOR pathway and its role as an insulin secretagogue. In cachexia the metabolism of arginine is 
altered making it an EAA. Arginine has improved immunological status and survival in surgical, 
malnourished head and neck cancer (Buijs et al. 2010). Similar to, but more potent in its muscle 
protein synthesis stimulatory effects than arginine, is citrulline. It is suggested that the 
effectiveness of citrulline over arginine is due to its superior absorption from the gut and the 
fact that it avoids hepatic uptakes. However, its effectiveness has only been demonstrated in 
healthy individuals and is yet to be investigated in patients with cancer. 
Creatine 
Creatine is a NEAA popular in research into athletes due to its role in rapid energy 
provision to skeletal muscle. There have been two recent studies in cancer. In a 6 week 
pediatric study, Bourgeois et al. (2008) investigated the effects of creatine on attenuating the 
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effects of glucocorticosteroids on skeletal muscle during chemotherapy. Nine children with 
acute lymphocytic leukemia were supplemented with 0.1g/kg body weight/day for 32 weeks. 
Over the course of the study, supplementation had no effect on BMI, weight or fat-free mass, 
but did appear to attenuate gains in fat mass (Bourgeois et al. 2008). However, this study was 
highly heterogeneous with large variance of age, disease stage and corticosteroid use. In a 
larger, well controlled double blind randomized controlled trial, Norman K. et al. (2006) 
investigated the effects of creatine supplementation vs placebo as a coadjuvant treatment in 
colorectal cancer over 8 weeks. In this study, supplementation had a positive effect in HGS, but 
not muscle function, body cell mass, nutritional parameters or quality of life.  
 
Conclusion 
Alterations in amino kinetics in patients with cancer lead to increased demands for 
protein and amino acids and to muscle wasting, sarcopenia and cachexia, which are all related 
to poor outcomes. This paper reviews human studies on amino acid kinetics and the response 
to nutrition in patients with cancer. These patients have a higher rate of whole body protein 
turnover and alterations in plasma amino acids. The most recent evidence-based guidelines for 
patients with cancer recommend a dietary protein intake of 1.0-1.5 g/kg body weight per day. 
There are promising results from supplementing EAAs or BCAAs on muscle protein synthesis. 
More research is needed into the optimal amount and quality of protein intake in patients with 
cancer, and how to target to different cohorts of patients with cancer, such as treatments or 
stages.  
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Research gaps 
Although there has been a lot of research done in healthy adults and older adults, in 
cancer there is a need for well-designed studies in homogenous groups of patients with cancer, 
investigating protein requirements and the effects of amino acids or proteins on muscle buildup 
and clinical outcomes. These are only a few examples for research questions to be addressed in 
the future:  
- What is the optimal dose, duration, frequency and route of administration required to 
stimulate muscle protein synthesis and does this differ between stages, type of cancer, 
treatment regimen, age groups? 
- What are the effects of long-term increased supplies of protein or modified protein 
quality / amino acid mixtures on muscle mass and clinical outcomes? 
- What is the effect of glutamine enriched nutrition on radiation-related skin toxicity, 
chemotherapy-related neuropathy, and mucositis? 
- What is the effect of combining an exercise program with protein supplementation on 
body composition, quality of life and clinical outcome, in curative as well as in palliative 
settings? 
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Figure captions 
Figure 1. Interaction of the TCA cycle, Nitric Oxide cycle and Urea cycle [adapted 
from: Ward (2015)] 
Figure 2. Methionine homocysteine cycle [adapted from Ward (2015)] 
Figure 3. Muscle metabolism of branched chain amino acids (BCAAs), glutamine 
and alanine [adapted from Leguina-Ruzzi and Cariqueo (2017)] 
Table captions 
Table 1.  Summary of disturbances in plasma amino acid levels in patients with 
cancer compared to healthy controls 
Table 2.  Digestible indispensable amino acid score (DIAAS) for common protein-
rich foods [adapted from Marinangeli and House (2017)] 
